Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7QPYK)

Drug Name

SKF-106760 Drug Info

Synonyms

126053-71-2; F 106760; Skf 106760; F-106760; Ac-Cyclo-S,S-(cys-(N(alpha)-Me)arg-gly-asp-pen)-NH2; AC1Q5IR2; AC1L4UF1; [(4r,7s,13s,16r)-16-(acetylamino)-4-carbamoyl-13-{3-[(diaminomethylidene)amino]propyl}-3,3,14-trimethyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecan-7-yl]acetic acid; CTK4B4925; L-Valinamide,N-acetyl-L-cysteinyl-N2-methyl-L-arginylglycyl-L-a-aspartyl-3-mercapto-, cyclic (1& 5)-disulfide (9CI)

Indication

Disease Entry	ICD 11	Status	REF
Thrombosis	DB61-GB90	Terminated	[1]

Cross-matching ID

PubChem CID: 44343680
TTD Drug ID: DM7QPYK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[3]
Eptifibatide	DMQXTJS	Acute cardiac ischemic events	BA40.Z	Approved	[4]
Tirofiban	DMQG17S	Acute coronary syndrome	BA41	Approved	[2]
Abciximab	DMJO6GV	Acute disease		Approved	[2]
DMP-444	DMO7BQS	Coronary artery disease	BA80	Phase 3	[5]
99mTc-rBitistatin	DMFAMNH	Pulmonary embolism	JB42	Phase 1/2	[6]
AjvW2	DM6PN4H	Thrombosis	DB61-GB90	Phase 1	[7]
SDZ-GPI-562	DMU9ZGN	Thrombosis	DB61-GB90	Phase 1	[8]
RGD-891	DMVJMF1	Thrombosis	DB61-GB90	Phase 1	[9]
Lefradafiban	DMKZVLH	Angina pectoris	BA40	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)	TT38RM1	ITA2B_HUMAN; ITB3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003995)
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76.
4	Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
5	Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4.
6	Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans. Nucl Med Biol. 2007 Oct;34(7):855-63.
7	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
8	Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost. 1999;25 Suppl 1:67-75.
9	Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56.
10	Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50.